GT Biopharma, Inc.
GTBP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $6 | $10 | $847 | $2,576 |
| - Cash | $4 | $1 | $6 | $9 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $9 | $841 | $2,567 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$13 | $6 | -$21 | -$57 |
| % Margin | – | – | – | – |
| Net Income | -$13 | -$8 | -$21 | -$58 |
| % Margin | – | – | – | – |
| EPS Diluted | -6.94 | -5.64 | -0.66 | -2.06 |
| % Growth | -23% | -754.5% | 68% | – |
| Operating Cash Flow | -$13 | -$9 | -$15 | -$16 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$13 | -$9 | -$15 | -$16 |